ONK Therapeutics

Main focus: Next-generation cell therapies for the treatment of cancer

Company stage: Pre-clinical

Diseases (gene editing): Multiple myeloma (MM), Acute myeloid leukaemia (AML), ovarian cancer, non-small cell lung cancer (NSCLC), breast cancer

Genome editing tool: CRISPR-Cas9

Funding stage: Private

Location: Galway, Republic of Ireland

Website: https://www.onktherapeutics.com/

Pipeline: https://www.onktherapeutics.com/pipeline/

Gene-editing partnerships: Intellia Therapeutics

ONK Therapeutics develops next-generation natural killer (NK) cell-based therapies for the treatment of cancer. The company tries to deploy multiple different knock-outs of different genes using CRISPR-Cas9 in its chimeric antigen receptor NK (CAR-NK) products. While the company is still conducting pre-clinical studies, it has disclosed multiple different haematological and solid tumour types that it will initially target. The company has established a collaboration with Intellia Therapeutics, which gives ONK Therapeutics non-exclusive rights to the CRISPR-Cas9 system and lipid nanoparticle (LNP) delivery technologies.

ONK Therapeutics